Prelude Capital Management’s Cytokinetics CYTK Stock Holding History

Prelude Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,100	Closed	-$222K	–	1337
2024 Q2	$222K	Buy	4,100 +100	+3%	+$6.04K	0.02%	941
2024 Q1	$280K	Buy	+4,000	New	+$309K	0.01%	926
2020 Q4	–	Sell	-900	Closed	-$19K	–	1413
2020 Q3	$19K	Buy	+900	New	+$21.1K	﹤0.01%	1332
2014 Q2	–	Sell	-2,000	Closed	-$19K	–	1958
2014 Q1	$19K	Buy	+2,000	New	+$18.1K	﹤0.01%	1698

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's CYTK Position: Q1 2026 in Review

Prelude Capital Management reduced its Cytokinetics (CYTK) stake by 42% in Q1 2026, selling an estimated $999K and leaving 21,813 shares worth $1.44M. The position accounts for 0.11% of the portfolio, ranked #221.

Prelude Capital Management first reported a position in CYTK in Q4 2013 and has held it in 34 quarters since. The position peaked at $2.39M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Prelude Capital Management held 21,813 shares of Cytokinetics worth $1.44M as of Q1 2026.
Prelude Capital Management sold 15,726 Cytokinetics shares in Q1 2026, an estimated $999K.
Cytokinetics made up 0.11% of Prelude Capital Management's portfolio in Q1 2026, its #221 holding.
Prelude Capital Management first reported a position in Cytokinetics in Q4 2013 and has held it in 34 quarters since.
Prelude Capital Management's Cytokinetics position peaked at $2.39M in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.